Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | DAO | P14920 | 1/20 | 0.35 |
| ▸ | FEN1 | P39748 | 1/20 | 0.34 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.32 |
| ▸ | CDK8 | P49336 | 1/20 | 0.31 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.31 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19006272 | 0.85 | DAO (0.33) | MEN1OPRM1OPRD1KMT2ADAO | |
| SCHEMBL18999245 | 0.81 | CTSK (0.35) | MEN1OPRM1OPRD1KMT2ADGAT1 | |
| SCHEMBL18982267 | 0.78 | MEN1 (0.36) | MEN1OPRM1OPRD1KMT2A | |
| SCHEMBL18982928 | 0.77 | KMT2A (0.33) | MEN1OPRM1OPRD1KMT2A | |
| SCHEMBL13819888 | 0.74 | DAO (0.36) | DAOFEN1TLR7ENPP3 | |
| SCHEMBL19006347 | 0.74 | PRSS1 (0.33) | MEN1OPRM1OPRD1KMT2A | |
| SCHEMBL18982483 | 0.73 | MEN1 (0.30) | MEN1OPRM1OPRD1KMT2A | |
| SCHEMBL18982387 | 0.73 | SLC6A2 (0.34) | MEN1OPRM1OPRD1KMT2A | |
| SCHEMBL18982161 | 0.72 | — | — | |
| SCHEMBL18982722 | 0.72 | MEN1 (0.31) | MEN1OPRM1OPRD1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3394067-B1 | 4-AMINO-2-(1H-PYRAZOLO[3,4-B]PYRIDIN-3-YL)-6-OXO-6,7-DIHYDRO-5H-PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES AND THE RESPECTIVE (1H-INDAZOL-3-YL) DERIVATIVES AS CGMP MODULATORS FOR TREATING CARDIOVASCULAR DISEASES | MERCK SHARP & DOHME (US) | 2020-04-01 | — | — | EP | disclosed |
| US-10428076-B2 | Soluble guanylate cyclase stimulators | MERCK SHARP & DOHME CORP. (US) | 2019-10-01 | — | — | US | disclosed |
| WO-2017107052-A1 | SOLUBLE GUANYLATE CYCLASE STIMULATORS | MERCK SHARP & DOHME CORP. (US) | 2017-06-29 | — | — | WO | disclosed |
| US-20170174693-A1 | SOLUBLE GUANYLATE CYCLASE STIMULATORS | MERCK SHARP & DOHME LLC | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174693-A1 | SOLUBLE GUANYLATE CYCLASE STIMULATORS | GUCY1A1, GUCY1A2, PDE2A | MEN1 1128/4885OPRM1 2221/4885OPRD1 2120/4885 |
| US-10428076-B2 | Soluble guanylate cyclase stimulators | GUCY1A1, GUCY1A2, PDE2A | MEN1 1128/4885OPRM1 2221/4885OPRD1 2120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.